• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD57(亮氨酸-7)表达有助于诊断甲状腺乳头状癌的滤泡变体。

CD57 (Leu-7) expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma.

作者信息

Khan A, Baker S P, Patwardhan N A, Pullman J M

机构信息

Department of Pathology, University of Massachusetts Medical Center, Worcester 01655, USA.

出版信息

Virchows Arch. 1998 May;432(5):427-32. doi: 10.1007/s004280050186.

DOI:10.1007/s004280050186
PMID:9645441
Abstract

CD57 (HNK-1) is a oligosaccharide antigen that is expressed by cells of several lineages. It is present on multipotential neuroepithelial cells during embryogenesis, and tumours of epithelial, neuroectodermal and nerve sheath origin also express CD57. Its role in the diagnosis of thyroid tumours is controversial. We have studied CD57 expression by immunohistochemistry to determine its utility in the classification of thyroid follicular lesions. Study material included 114 normal thyroid sections, 77 benign thyroid lesions (29 colloid nodules, 22 follicular adenomas, 20 cases of Hashimoto's thyroiditis and 6 of Grave's disease) and 83 thyroid carcinomas, including 31 follicular variants of papillary carcinoma. We observed CD57 positivity in 95% of thyroid carcinomas, 27% of follicular adenomas and 10% of colloid nodules. It was not expressed in the normal thyroid. CD57 expression in thyroid carcinomas was significantly different from that in normal and benign thyroid lesions (P < 0.0001). The follicular variant of papillary thyroid carcinoma also showed significantly higher CD57 expression than colloid nodules (P < 0.0009) or follicular adenomas (P < 0.0009). No significant difference was seen between colloid nodules and follicular adenomas. We conclude that CD57 immunohistochemistry is valuable in the classification of thyroid follicular lesions into benign and malignant groups and is also helpful in the diagnosis of the follicular variant of papillary thyroid carcinoma.

摘要

CD57(HNK-1)是一种寡糖抗原,由多个谱系的细胞表达。在胚胎发育过程中,它存在于多能神经上皮细胞上,上皮、神经外胚层和神经鞘来源的肿瘤也表达CD57。其在甲状腺肿瘤诊断中的作用存在争议。我们通过免疫组织化学研究了CD57的表达,以确定其在甲状腺滤泡性病变分类中的效用。研究材料包括114例正常甲状腺切片、77例良性甲状腺病变(29例胶样结节、22例滤泡性腺瘤、20例桥本甲状腺炎和6例格雷夫斯病)以及83例甲状腺癌,其中包括31例乳头状癌的滤泡变体。我们观察到95%的甲状腺癌、27%的滤泡性腺瘤和10%的胶样结节中存在CD57阳性。正常甲状腺中未表达CD57。甲状腺癌中的CD57表达与正常和良性甲状腺病变中的表达有显著差异(P<0.0001)。甲状腺乳头状癌的滤泡变体也显示出比胶样结节(P<0.0009)或滤泡性腺瘤(P<0.0009)显著更高的CD57表达。胶样结节和滤泡性腺瘤之间未观察到显著差异。我们得出结论,CD57免疫组织化学在将甲状腺滤泡性病变分为良性和恶性组方面有价值,并且在甲状腺乳头状癌滤泡变体的诊断中也有帮助。

相似文献

1
CD57 (Leu-7) expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma.CD57(亮氨酸-7)表达有助于诊断甲状腺乳头状癌的滤泡变体。
Virchows Arch. 1998 May;432(5):427-32. doi: 10.1007/s004280050186.
2
Leu-7 immunoreactivity in cytologic specimens of thyroid lesions, with emphasis on follicular neoplasms.
Diagn Cytopathol. 1995 Jun;12(4):297-302. doi: 10.1002/dc.2840120403.
3
Diagnostic value of CD56 immunohistochemistry in thyroid lesions.CD56免疫组化在甲状腺病变中的诊断价值
Int J Biol Markers. 2018 May;33(2):161-167. doi: 10.1177/1724600817748538.
4
Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.甲状腺乳头状癌及可能与甲状腺乳头状癌相关的良性甲状腺结节的免疫组织化学研究
Pathol Res Pract. 2000;196(8):533-40. doi: 10.1016/s0344-0338(00)80025-4.
5
Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas.甲状腺嗜酸细胞腺瘤和癌中半乳糖凝集素-3的差异反应性。
Endocr Pathol. 2001 Fall;12(3):275-9. doi: 10.1385/ep:12:3:275.
6
Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray.组织芯片中甲状腺滤泡性病变的三叶因子3免疫组织化学特征
Arch Otolaryngol Head Neck Surg. 2009 Jun;135(6):590-6. doi: 10.1001/archoto.2009.54.
7
Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.甲状腺肿瘤中的细胞角蛋白亚型:着重于乳头状癌滤泡变体的免疫组织化学研究
J Otolaryngol. 2003 Oct;32(5):319-22. doi: 10.2310/7070.2003.11429.
8
Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link?p63在甲状腺乳头状癌和桥本甲状腺炎中的表达:一种病理生物学联系?
Hum Pathol. 2003 Aug;34(8):764-9. doi: 10.1016/s0046-8177(03)00239-9.
9
Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and hashimoto's thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis.p53 同源物 p63 在实性细胞巢、甲状腺乳头状癌及桥本甲状腺炎中的免疫组化检测:甲状腺乳头状癌发生的干细胞假说
Hum Pathol. 2004 Apr;35(4):465-73. doi: 10.1016/j.humpath.2003.10.027.
10
MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma.微小RNA分析作为甲状腺乳头状癌的一种潜在诊断工具
Mod Pathol. 2008 Sep;21(9):1139-46. doi: 10.1038/modpathol.2008.105. Epub 2008 Jun 27.

引用本文的文献

1
Clinical and Histopathological Factors Associated with the Tumoral Expression of TGF-1, MED15, CD16, and CD57 in Oral Squamous Cell Carcinoma.口腔鳞状细胞癌中与转化生长因子-1、MED15、CD16和CD57肿瘤表达相关的临床和组织病理学因素
Adv Prev Med. 2022 Oct 27;2022:3145117. doi: 10.1155/2022/3145117. eCollection 2022.
2
Emerging Biomarkers in Thyroid Practice and Research.甲状腺临床与研究中的新兴生物标志物
Cancers (Basel). 2021 Dec 31;14(1):204. doi: 10.3390/cancers14010204.
3
Evaluation of natural killer cell (CD57) as a prognostic marker in oral squamous cell carcinoma: An immunohistochemistry study.
自然杀伤细胞(CD57)作为口腔鳞状细胞癌预后标志物的评估:一项免疫组织化学研究。
J Oral Maxillofac Pathol. 2016 May-Aug;20(2):173-7. doi: 10.4103/0973-029X.185933.
4
Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.胰岛素样生长因子mRNA结合蛋白3(IMP3)在良性和恶性滤泡型甲状腺肿瘤中表达存在差异。
Endocr Pathol. 2009 Fall;20(3):149-57. doi: 10.1007/s12022-009-9079-x.
5
Neuroendocrine marker expression in thyroid epithelial tumors.
Endocr Pathol. 2001 Fall;12(3):291-9. doi: 10.1385/ep:12:3:291.
6
Clinical implications of biomarkers in head and neck cancer.生物标志物在头颈癌中的临床意义
Curr Oncol Rep. 1999;1(2):129-37. doi: 10.1007/s11912-999-0023-5.